Trial reportAsian journal of andrology
Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
Trial report in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.The Prostate · 2017Trial
- Comparative analysis of genetic risk scores for predicting biochemical recurrence in prostate cancer patients after radical prostatectomy.BMC urology · 2024Article
- Utility of polygenic scores across diverse diseases in a hospital cohort for predictive modeling.Nature communications · 2024Article
- Determining the role of genetic risk scores in symptomatic cancer detection.The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Article
- Predicting 10-Year Risk of Pancreatic Cancer Using a Combined Genetic and Clinical Model.Gastro hep advances · 2023Article
- Antioxidant enzyme and DNA base repair genetic risk scores' associations with systemic oxidative stress biomarker in pooled cross-sectional studies.Frontiers in aging · 2023Article
- Novel clinical, molecular and bioinformatics insights into the genetic background of autism.Human genomics · 2022Article
- Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?Asian journal of urology · 2021Review
- Review
- Validation of a prostate cancer polygenic risk score.The Prostate · 2020Article
- New variants in NLRP3 inflammasome genes increase risk for asthma andCytokine: X · 2020Article
- Inherited risk assessment of prostate cancer: it takes three to do it right.Prostate cancer and prostatic diseases · 2020Review
- Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.JAMA network open · 2019Article
- Prioritization of Variants for Investigation of Genotype-Directed Nutrition in Human Superpopulations.International journal of molecular sciences · 2019Article
- Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts.Cancer medicine · 2019Article
- Selecting variants of unknown significance through network-based gene-association significantly improves risk prediction for disease-control cohorts.Scientific reports · 2019Article
- Current progress and questions in germline genetics of prostate cancer.Asian journal of urology · 2019Review
- Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study.Oncotarget · 2017Article
- A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.Current opinion in urology · 2017Review
- Clinical validity and utility of genetic risk scores in prostate cancer.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several different approaches are available to clinicians for determining prostate cancer (PCa) risk. The clinical validity of various PCa risk assessment methods utilizing single nucleotide polymorphisms (SNPs) has been established; however, these SNP-based methods have not been compared. The objective of this study was to compare the three most commonly used SNP-based methods for PCa risk assessment. Participants were men (n = 1654) enrolled in a prospective study of PCa development. Genotypes of 59 PCa risk-associated SNPs were available in this cohort. Three methods of calculating SNP-based genetic risk scores (GRSs) were used for the evaluation of individual disease risk such as risk allele count (GRS-RAC), weighted risk allele count (GRS-wRAC), and population-standardized genetic risk score (GRS-PS). Mean GRSs were calculated, and performances were compared using area under the receiver operating characteristic curve (AUC) and positive predictive value (PPV). All SNP-based methods were found to be independently associated with PCa (all P < 0.05; hence their clinical validity). The mean GRSs in men with or without PCa using GRS-RAC were 55.15 and 53.46, respectively, using GRS-wRAC were 7.42 and 6.97, respectively, and using GRS-PS were 1.12 and 0.84, respectively (all P < 0.05 for differences between patients with or without PCa). All three SNP-based methods performed similarly in discriminating PCa from non-PCa based on AUC and in predicting PCa risk based on PPV (all P > 0.05 for comparisons between the three methods), and all three SNP-based methods had a significantly higher AUC than family history (all P < 0.05). Results from this study suggest that while the three most commonly used SNP-based methods performed similarly in discriminating PCa from non-PCa at the population level, GRS-PS is the method of choice for risk assessment at the individual level because its value (where 1.0 represents average population risk) can be easily interpreted regardless of the number of risk-associated SNPs used in the calculation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.